Experimental therapeutics in transgenic mouse models of Huntington's disease

Nature Reviews Neuroscience

Volumn 5, Issue 5, 2004, Pages 373-384

  Beal, M Flint ^a   Ferrante, Robert J ^b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BN 82451; BUTYRIC ACID; CALPAIN; CASPASE; CONGO RED; CREATINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYSTAMINE; DRINKING WATER; GELDANAMYCIN; HUNTINGTIN; LITHIUM CHLORIDE; MINOCYCLINE; MITHRAMYCIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; REMACEMIDE; RILUZOLE; TAURODEOXYCHOLIC ACID; THIOCTIC ACID; TREHALOSE; TRIACETYLURIDINE; UBIDECARENONE; UNCLASSIFIED DRUG; URIDINE DERIVATIVE; VORINOSTAT;

APOPTOSIS; BRAIN MITOCHONDRION; CAENORHABDITIS ELEGANS; CLINICAL PATHWAY; DISEASE COURSE; DISEASE MODEL; DROSOPHILA MELANOGASTER; DRUG MECHANISM; DRUG TARGETING; GENE; GENE MUTATION; HD GENE; HUNTINGTON CHOREA; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SURVIVAL; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

CAENORHABDITIS; CAENORHABDITIS ELEGANS; DROSOPHILA MELANOGASTER; MELANOGASTER; MUS MUSCULUS;

EID: 2342598416     PISSN: 1471003X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrn1386     Document Type: Review

References (142)

1. Huntington, G. On chorea. Med. Surg. Rep. 26, 317-321 (1872).
2. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983 (1993).
3. Gunawardena, S. et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ in Drosophila. Neuron 40, 25-40 (2003). A well-done study showing that overexpression of pathologic polyQ in D. melanogaster disrupts fast axonal transport and that this precedes transcriptional dysfunction.
4. Szebenyi, G. et al. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40, 41-52 (2003). Evidence that mutant polyglutamine-containing proteins directly inhibit fast axonal transport in isolated axoplasm from squid giant axons.
5. Trushina, E. et al. Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease. Proc. Natl. Acad. Sci. USA 21, 12171-12176 (2003).
6. Goodman, N. et al. Plans for HD base - a research community website for Huntington's disease. Clin. Neurosci. Res. 3, 197-217 (2003).
7. Mangiarini, L. et al. Exon 1 of the HD gene with expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 187, 493-506 (1996).
8. Hockly, E. et al. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51, 235-242 (2002).
9. Carter, R. J., Hunt, M. J. & Morton, J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord 15, 925-937 (2000).
10. Van Dellen, A., Blakemore, C., Deacon, R., York, D. & Hannan, J. Delaying the onset of Huntington's in mice. Nature 404, 721-722 (2000).
11. Spires, T. L. et al. Envrironmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J. Neurosci. 29, 2270-2276 (2004).
12. Schilling, G. et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397-407 (1999).
13. Yu, Z.-X. et al. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 23, 2193-2202 (2003). An interesting paper showing differential effects of mutant huntingtin on neurodegeneration depending on the length of the pathologic protein.
14. Duan, W. et al. Dietary restriction mornalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl Acad. Sci. USA 97, 8093-8097 (2003). This study shows improvement with dietary restriction in the N171-82Q HD mice.
15. Andreassen, O. A. et al. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol. Dis. 11, 410-424 (2002).
16. Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66 (2000).
17. Shelbourne, P. F. et al. A Huntington's diseae CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet. 8, 763-774 (1999).
18. Li, H., Li, S. H., Yu, Z.-X., Shelbourne, P. & Li, X. J. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 21, 8473-8481 (2001). A study showing that neuropil aggregates and axonal degeneration are early events in a knock-in transgenic mouse model of HD.
19. Q111 knock-in-mice. Hum. Mol. Genet. 9, 503-513 (2000).
20. Wheeler, V. C. et al. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum. Mol. Genet. 11, 633-640 (2002).
21. Lin, C-H. et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 10, 137-144 (2001).
22. Menalled, L. B. et al. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci. 22, 8266-8276 (2002). Description of behavioural abnormalities and neuropathology in a knock-in transgenic mouse model of HD.
23. Reddy, P. H. et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nature Genet. 20, 198-202 (1998).
24. Slow, E. J. et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington's disease. Hum. Mol. Genet. 12, 1555-1567 (2003). Description of a full-length YAC transgenic mouse model of HD that develops cell loss in the striatum and cerebral cortex.
25. Li, C., Yang, W., Gong, S. & Heintz, N. Transgenic mouse models of full-length Huntington's disease gene with BAC modification models. Soc. Neurosci. Abstr. 130.9 (2003).
26. Hockly E., Woodman, B., Mahal, A., Lewis, C. M. & Bates, G. Standardization and statistical approached to therapeutic trials in the R6/2 mouse. Brain Res. Bull. 61, 469-479 (2003).
27. Goldberg, Y. P. et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genet. 4, 442-449 (1996).
28. Wellington, C. L. et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22, 7862-7872 (2002). A paper showing that caspase of mutant huntingtin is necessary for its toxicity.
29. Kim, Y. J. et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl Acad. Sci. USA 98, 12784-12789 (2001).
30. Gafni, J. & Ellerby, L. M. Calpain activation in Huntington's disease. J. Neurosci. 22, 4842-4849 (2002). An excellent study showing that calpain cleaves huntingtin and that fragments of the appropriate size are found in HD post-mortem brain tissue.
31. Bizat, N. et al. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J. Neurosci. 23, 5020-5030 (2003). This paper shows that calpain rather then the caspases mediate the neurotoxicity produced by chronic 3-NP administration.
32. Lunkes, A. et al. Proteases acting on mutant huntingtin generate cleaved products that differtially build up cytoplasmic and nuclear inclusion. Mol. Cell 10, 259-269 (2002). A study showing that a novel aspartyl protease cleaves mutant huntingtin near the N-terminus.
33. Caserta, T. M., Smith, A. N., Gultice, A. D., Reedy, M. A. & Brown, T. L Q-VD-Oph, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 8, 345-352 (2003). This paper describes a novel non-toxic broad-spectrum systemically active caspase inhibitor.
34. Friedlander, R. M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 348, 1365-1375 (2003).
35. Kiechle, T. et al. Cytochrome C and caspase-9 expression in Huntington's disease. Neuromolecular Med. 3, 183-195 (2002).
36. Sanchez, I. et al. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22, 623-633 (1999).
37. Ona, V. O. et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399, 263-267 (1999).
38. Turmaine, M. et al. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 97, 8093-8097 (2000).
39. Senatorov, V. V, Charles, V., Reddy, P. H., Tagle, D. A. & Chuang D. M. Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 22, 285-297 (2003).
40. Wang, X. et al. Minocycline inhibits caspase-independent and dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. USA 100, 10483-10487 (2003).
41. Chen, M. et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease. Nature Med. 7, 797-801 (2000). The first study showing efficacy of minocycline in the R6/2 transgenic mouse model of HD.
42. Smith, D. L. et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann. Neurol. 54, 186-196 (2003).
43. Yang, L. et al. Minocycline enchances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res. 74, 278-285 (2003).
44. Keene, C. D. et al. Tauroursodeoxycholic acid, a bile acid is neuroprotective in a transgenic animal model of Huntington's disease. Proc. Natl Acad. Sci. USA 99, 10671-10676 (2002).
45. Yang, W., Dunlap, J. R., Andrews, R. B. & Wetzel, R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11, 2905-2917 (2002).
46. Poirier, M. A. et al. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrillization. J. Biol. Chem. 277, 41032-41037 (2002).
47. Sanchez, I., Mahike, C. & Yuan, J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373-379 (2003). A paper showing that congo red, which blocks oligomerization of huntingtin exerts neuroprotective effects and extends survival in a transgenic mouse model of HD.
48. Heiser, V. et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc. Natl Acad. Sci. USA 99, 16400-16406 (2002). Description of a high throughput assay to identify inhibitors of huntingtin aggregation.
49. Sittler, A. et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum Mol. Genet. 10, 1307-1315 (2001).
50. Ravikumar, B., Duden, R. & Rubinsztein, D. C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11, 1107-1117 (2002).
51. Tanaka, M. et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nature Med. 10, 148-154 (2004). An excellent and comprehensive study showing that disaccharides inhibit polyglutamine aggregation. Administration to transgenic mice improved motor performance and survival, and decreased striatal atrophy and numbers of huntingtin aggregates.
52. Lin, X., Antalffy, B., Kang, D., Orr, H. T. & Zoghbi, H. Y. Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nature Neurosci. 3, 103-104 (2000).
53. La Spada, A. R. et al. Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 32, 957-958 (2001).
54. Okazawa, H. et al. Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 34, 701-713 (2002).
55. Luthi-Carter, R. et al. Decreased expansion of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9, 1259-1271 (2000). A study showing that there is impaired gene transcription in the R6/2 mouse model of HD.
56. Chan, E. et al. Increased huntingtin protein length reduced the number of polyglutamine-induced gene expression changes in mouse models of Hungtington's disease. Hum. Mol. Genet. 11, 1939-1951 (2002).
57. Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D. & Housman, D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl Acad. Sci. USA 96, 11404-11409 (1999).
58. Nucifora, F. C. Jr et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423-2428 (2001).
59. Steffan, J. S. et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA 97, 6763-6768 (2000).
60. McCampbell, A. et al. CREB-binding protein sequestration by expanded polyglutamine. J. Hum. Mol. Genet. 9, 2197-2202 (2000).
61. Mantamadiotis, T. et al. Disruption of CREB function in brain leads neurodegeneration. Nature Genet. 31, 47-54 (2002). A study showing that post-natal conditional disruption of CREB leads to neuronal degeneration in the striatum and hippocampus.
62. Obrietan, K. & Hoyt, K. R. CRE-mediated transcription is increased in Huntington's disease transgenic mice. J. Neurosci. 24, 791-796 (2004). A nicely done study which convincingly shows Increased CRE-mediated transcription in the R6/2 transgenic mouse model of HD.
63. Boutell, J. M. et al. Abberant interactions of transcriptional repressor proteins with the Huntingon's disease gene product, huntingtin. Hum. Mol. Genet. 8, 1647-1655 (1999).
64. Suhr, S. T. et al. Identities of sequestered proteins in aggregates from cells with induced polyglutamate expression. J. Cell Biol. 153, 283-294 (2001).
65. II130, interfering with CREB-dependent transcription. Nature Genet. 26, 29-36 (2000).
66. Li, S. H. et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol. 22, 1277-1287 (2002). A study showing that soluble mutant huntingtin interacts with and inhibits the transcriptional activator SP1.
67. II130 transcription is impaired in HD, and that SP1 overexpression protects against toxic effects of mutant huntingtin.
68. McCampbell, A. et al. Histone deecetylase inhibitors reduce polyglutamate toxicity. Proc. Natl Acad. Sci. USA 98, 15179-15184 (2001).
69. Ryu, H. et al. Histone deacetylase inhibitors prevent oxidfative neuronal death independent of expanded polyglutamine repeats via an Sp-1 dependent pathway. Proc. Natl Acad. Sci. USA 100, 4281-4286 (2003).
70. Steffan, J. S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in drosophila. Nature 413, 739-743 (2001).
71. Hockly, E. et al. Suberaylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 2041-2046 (2003). A study showing inproved rotarod performance with the HDAC inhibitor SAHA. This was the first demonstration that SAHA, and which has benefits in yeast and D. melanogaster, also shows benefits in a transgenic mouse model of HD.
72. Ferrante, R. J. et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418-9427 (2003). The first paper to show that inhibition of HDACs by butyrate improves survival, behaviour and the neuropathologic change in the R6/2 transgenic mice when administered presymptomatically.
73. Burlina, A. B., Ogler, H. & Trefz, F. K. Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients. Mol. Genet. Metab. 72, 351-355 (2001).
74. Maestri, N. E., Brusilow, S. W., Clissold, D. B. & Bassett, S. S. Long-term treatment of girls with ornithine transcarbamylase deficiency. N. Engl J. Med. 335, 855-859 (1996).
75. Ferrante, R. J. et al. Therapeutic effects of mithramycin in R6/2 transgenic Huntington's disease mice. Soc. Neurosci. Abstr. 28, 725 (2002).
76. Jenkins, B. G., Koroshetz, W. J., Beal, M. F. & Rosen, B. R. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43, 2689-2695 (1993).
77. Koroshetz, W. J., Jenkins, B. G., Rosen, B. R. & Beal, M. F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41, 160-165 (1997).
78. Lodi, R. et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 48, 72-76 (2000).
79. Beal, M. F. et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181-4192 (1993).
80. Brouillet, E. et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl Acad. Sci. USA 92, 7105-7109 (1995).
81. Sawa, A. et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nature Med. 5, 1194-1198 (1999).
82. Panov, A. V. et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neurosci. 5, 7313-736 (2002). The first paper to show that huntingtin directly interacts with mitochondria resulting in lowered membrane potential and impaired ability to take up calcium
83. Q111-knock-in mice show a progressive depletion of cAMP and ATP levels consistent with mitochondrial dysfunction.
84. Sanchez-Pernaute, R., Garcia-Segura, J. M., del Barrio Alba, A., Viano, J. & de Yebenes, J. G. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 53, 806-812 (1999).
85. Gu, M. et al. Mitochondrial defect in Hungtington's disease caudate nucleus. Ann. Neurol. 39, 385-389 (1996).
86. Browne, S. E. et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653 (1997).
87. Herzig, R. P., Scacco, S. & Scarpulla, R. C. Sequential serum-dependent activation of CREB and NRF-1 leads to enhanced mitochondrial respiration through the induction of cytochrome c. J. Biol. Chem. 275, 13134-13141 (2000).
88. Matthews, R. T. et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 18, 156-163 (1998).
89. Ferrante, R. J. et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389-4397 (2000). The first agent to show neuroprotective effects in the R6/2 mice.
90. Dedeoglu, A. et al. Creatine therapy provides neuroprotection after onset of clinical symptoms of Huntington's disease transgenic mice. J. Neurochem. 85, 1359-1367 (2003).
91. Andreassen, O. A. et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's Disease. Neurobiol. Dis. 8, 479-491 (2001).
92. Andreassen, O. A. et al. Dichloroacetate exerts therapeutic effects in trangenic mouse models of Huntington's disease. Ann. Neurol. 50, 112-117 (2001).
93. Beal, M. F. et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181-4192 (1993).
94. Brouillet, E. et al. Chronic mitochondrial energy impairment produces selective striatal degenerative and abnormal choreiform movements in primates. Proc. Natl Acad. Sci. USA 92, 7105-7109 (1995).
95. Hansson, O. et al. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl Acad. Sci. USA 96, 8727-8732 (1999).
96. Hansson, O. et al. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J. Neurochem. 78, 694-703 (2001).
97. Petersen, A. et al. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Exp. Neurol. 175, 297-300 (2002).
98. Zeron, M. M. et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Hungtington's disase. Neuron 33, 849-960 (2002). A paper showing that YAC full-length HD transgenic mice show increased susceptibility to NMDA-mediated excitotoxicity.
99. Noack, H., Kube, U. & Augustin, W. Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. Free Radic. Res. 20, 375-386 (1994).
100. 10 reduced the toxicity of retenone in neuronal cultures by preserving the mitochondrial membrane potential. Biofactors 18, 65-72 (2003).
101. 10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J. Biol. Chem. 278, 28220-28228 (2003).
102. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann. Neurol. 36, 882-888 (1994).
103. 10 and remacemide in the R6/2 transgenic mouse model of HD.
104. 10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosi. Lett. 315, 149-153 (2001).
105. Schiefer, J. et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord. 4, 748-757 (2002).
106. Huntington Study Group. Dosage effects of riluzole in Huntington's disease. A multicenter placebo-controlled study. Neurology 61, 1551-1556 (2003).
107. Wood, N. I. & Morton A. J. Chronic lithium chloride treatment has variable effects on motor behavior and survival of mice transgenic for the Huntington's disease mutation. Brain Res. Bull. 61, 375-383 (2003)
108. Guiliano, P. et al. DNA damage induced by polyglutamine-expanded proteins. Hum. Mol. Genet. 18, 2301-2309 (2003).
109. Browne, S. E., Ferrante, R. J. & Beal, M. F. Oxidative stress in Huntington's disease. Brain Pathol. 9, 147-163 (1999).
110. Tabrizi, S. J. et al. Mitochondrial dysfunction and free radical change in the Huntingtin R6/2 transgenic mouse. Ann. Neurol. 47, 80-86 (2000).
111. Perez-Severiano, F., Rios, C. & Segovia, J. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. 862, 234-237 (2000).
112. Bogdanov, M. B., Andreassen, O. A., Dedeoglu, A., Ferrante, R. J. & Beal, M. F. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 79, 1246-1249 (2001).
113. Andreassen, O. A., Ferrante, R. J., Dedeoglu, A. & Beal, M. F. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 12, 3371-3373 (2001).
114. Mackenson, G. B. et al. Neuroprotection from delayed postischemic administration of a metalloporohyrin catalytic antioxidant. J. Neurosci. 21, 4582-4592 (2001).
115. Ginsberg, M. D. et al. Stilbazulenyl nitrone, a novel antioxidant, is highly neuroprotective in focal ischemia. Ann. Neurol. 54, 330-342 (2003).
116. Sapp, E. et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60, 161-172 (2001).
117. Klivenyi, P. et al. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J. Neurochem. 86, 267-272 (2003).
118. Cooper, A. J. et al. Transglutaminase- catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and α-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. Proc. Natl Acad. USA 94, 12604-12609 (1997).
119. Kahlem, P., Green, H. & Dijan P. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntington containing expanded polyglutamine. Mol. Cell. 1, 595-601 (1998).
120. Gentile, V. et al. Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. Arch. Biochem. Biophys. 352, 314-321 (1998).
121. Igarashi, S. et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with expanded polyglutamine stretch. Nature Genet. 18, 111-117 (1998).
122. Karpuj, M. V. et al. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl Acad. Sci. USA 96, 7388-7393 (1999).
123. Lesort, M., Chun, W., Johnson, G. V. & Ferrante R. J. Tissue transglutaminase in increased in Huntington's disease brain. J. Neurochem. 73, 2018-2027 (1999).
124. Dedeoglu, A. et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22, 8942-8950 (2002). A paper showing that cystamine blocks aggregates and prolongs survival in the R6/2 transgenic mouse model of HD.
125. Jeitner, T. M. et al. Nε-γ-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J. Neurochem. 79, 1109-1112 (2001).
126. Zainelli, G. M., Ross, C. A., Troncoso, J. C. & Muma, N. A. Transglutaminase cross-links in intranuclear inclusions in Huntington disease. J. Neuropathol. Exp. Neurol. 62, 14-24 (2003).
127. Lesort, M., Lee, M., Tucholski, J. & Johnson, G. V. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamate disorders. J. Biol. Chem. 278, 3825-3830 (2003).
128. Karpuj, M. V. et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nature Med. 8, 143-149 (2002). The first study to show efficacy of cystamine in the R6/2 mice.
129. Miller, T. W., Shirley, T. L., Wolfgang, W. J., Kang, X. & Messer, A. DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol. Ther. 7, 572-579 (2003).
130. Greenberg, S. M., Backsai, B. J. & Hyman, B. T. Alzheimer disease's double-edged vaccine. Nature Med. 9, 389-390 (2003).
131. Dunnett, S. B. et al. Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp. Neurol. 154, 31-40 (1998).
132. van Dellen, A., Deacon, R., York, D., Blakemore, C. & Hannan, A. J. Anterior cingulate cortical transplantation in transgenic Huntington's disease mice. Brain Res. Bul. 56, 313-318 (2001).
133. Guara, V. et al. Striatal neural grafting improves cortical metabolism in Hungtington's disease patients. Brain 127, 65-72 (2003).
134. von Horsten, S. et al. Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 12, 617-624 (2003). Description of a new transgenic rat model of HD.
135. Deckel, A. W. et al. Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: effects of L-NAME on symptom progression. Brain Res. 919, 70-81 (2001).
136. Deckel, A. W., Tang, V., Nuttal, D., Gary, K. & Elder, R. Altered neuronal nitric oxide synthase expression contributes to disease progression in Hungtington's disease in transgenic mice. Brain Res. 939, 76-86 (2002).
137. 10 in HD.
138. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59, 1541-1550 (2002).
139. Klivenyi, P., Kiaei, M., Gardian, G., Calingasan, N. Y. & Beal, M. F. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of ALS. J. Neurochem. 88, 576-583 (2004).
140. Apostol, B. L. et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl Acad. Sci. USA 100, 5950-5955 (2003). A study showing that cell-based high throughput screening for aggregation inhibitors identifies compounds that show efficacy in D. melanogaster.
141. Pollitt, S. K. et al. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron 40, 685-694 (2003). This study screened over 2,800 small molecules using fluorescence resonance energy transfer (FRET) to measure intracellular polyglutamine protein aggregation. The authors characterized one compound, Y-27632, which is an inhibitor of the Rho-associated kinase p160ROCK. This compound showed efficacy in a D. melanogaster model of polyglutamine diseases.
142. Kazantsev, A. et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in drosophila. Nature Genet. 30, 367-376 (2002). A study showing that a novel inhibitor of huntingtin aggregation is effective D. melanogaster.